$0.1425
-0.0155[-9.81%]
At close: Apr 26
$0.1425
0[0.00%]
After Hours: 7:58PM EDT
Kintara Therapeutics
(NASDAQ:KTRA)Kintara Therapeutics Stock (NASDAQ:KTRA), Analyst Ratings, Price Targets, Predictions
Kintara Therapeutics Inc has a consensus price target of $5.5, established from looking at the 6 latest analyst ratings. The last 3 analyst ratings were released from Maxim Group, Maxim Group, and Dawson James on July 14, 2023, September 29, 2022, and May 16, 2022. With an average price target of $4.67 between Maxim Group, Maxim Group, and Dawson James, there's an implied 3174.85% upside for Kintara Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Maxim Group
Dawson James
HC Wainwright & Co.
Aegis Capital
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Kintara Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 07/14/2023 | KTRA | Buy Now | Kintara Therapeutics | $0.14 | 9724.56% | Maxim Group | Jason McCarthy | → $14 | Upgrade | Hold → Buy | Get Alert |
| 09/29/2022 | KTRA | Buy Now | Kintara Therapeutics | $0.14 | — | Maxim Group | Jason McCarthy | — | Downgrade | Buy → Hold | Get Alert |
| 05/16/2022 | KTRA | Buy Now | Kintara Therapeutics | $0.14 | — | Dawson James | Jason Kolbert | — | Downgrade | Buy → Neutral | Get Alert |
| 01/20/2022 | KTRA | Buy Now | Kintara Therapeutics | $0.14 | 2005.26% | HC Wainwright & Co. | Michael King | $300 → $150 | Maintains | Buy | Get Alert |
| 09/30/2021 | KTRA | Buy Now | Kintara Therapeutics | $0.14 | 3408.77% | Aegis Capital | Nathan Weinstein | — | Maintains | Buy | Get Alert |
| 09/28/2021 | KTRA | Buy Now | Kintara Therapeutics | $0.14 | 4110.53% | HC Wainwright & Co. | Michael King | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Kintara Therapeutics (KTRA)?
The latest price target for Kintara Therapeutics (NASDAQ: KTRA) was reported by Maxim Group on July 14, 2023. The analyst firm set a price target for $14.00 expecting KTRA to rise to within 12 months (a possible 9724.56% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Kintara Therapeutics (KTRA)?
The latest analyst rating for Kintara Therapeutics (NASDAQ: KTRA) was provided by Maxim Group, and Kintara Therapeutics upgraded their buy rating.
When was the last upgrade for Kintara Therapeutics (KTRA)?
The last upgrade for Kintara Therapeutics Inc happened on July 14, 2023 when Maxim Group raised their price target to $14. Maxim Group previously had a hold for Kintara Therapeutics Inc.
When was the last downgrade for Kintara Therapeutics (KTRA)?
The last downgrade for Kintara Therapeutics Inc happened on September 29, 2022 when Maxim Group changed their price target from N/A to N/A for Kintara Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Kintara Therapeutics (KTRA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kintara Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kintara Therapeutics was filed on July 14, 2023 so you should expect the next rating to be made available sometime around July 14, 2024.
Is the Analyst Rating Kintara Therapeutics (KTRA) correct?
While ratings are subjective and will change, the latest Kintara Therapeutics (KTRA) rating was a upgraded with a price target of $0.00 to $14.00. The current price Kintara Therapeutics (KTRA) is trading at is $0.14, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.